RecruitingPhase 4NCT07501065

Prophylactic Antibiotics for Outpatient Urethral Bulking

Prophylactic Antibiotics for Outpatient Urethral Bulking: Impact on Post-Procedural Urinary Tract Infection Rates

Sponsor

University of Miami

Enrollment

150 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Urinary Incontinence Stress Urinary Incontinence Urinary Tract Infections

Summary

The purpose of this study is to evaluate whether taking prophylactic (preventative) antibiotics at the time of standard of care clinic-based urethral bulking reduces the risk of post-procedural urinary tract infection (UTI).

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg) for people with stress urinary incontinence, urinary incontinence, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg)

Participants will receive a single oral dose of either Bactrim (800 mg sulfamethoxazole + 160 mg trimethoprim), Keflex (500 mg cephalexin), Cipro (250 mg ciprofloxacin), or if allergic to sulfonamides, a single oral dose of Macrobid (100 mg nitrofurantoin) at the time of the urethral bulking procedure.